Cantor Fitzgerald Estimates NeuroPace FY2025 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of NeuroPace in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will earn ($0.79) per share for the year. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The business had revenue of $21.06 million during the quarter, compared to analysts’ expectations of $19.33 million. During the same period in the prior year, the company earned ($0.28) earnings per share.

Several other brokerages also recently weighed in on NPCE. UBS Group began coverage on NeuroPace in a report on Tuesday. They set a “buy” rating and a $17.00 price target for the company. Wells Fargo & Company lowered their target price on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. increased their price target on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.33.

NeuroPace Trading Up 4.8 %

Shares of NPCE stock opened at $14.69 on Thursday. The company has a market capitalization of $438.50 million, a P/E ratio of -14.69 and a beta of 2.02. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The business’s 50 day moving average is $11.34 and its two-hundred day moving average is $8.61. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.15.

Hedge Funds Weigh In On NeuroPace

Several hedge funds have recently bought and sold shares of NPCE. JPMorgan Chase & Co. increased its position in NeuroPace by 106.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock worth $84,000 after purchasing an additional 6,181 shares in the last quarter. Rhumbline Advisers purchased a new position in NeuroPace during the second quarter worth approximately $111,000. Financial Advocates Investment Management boosted its holdings in shares of NeuroPace by 20.0% in the 3rd quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after purchasing an additional 3,000 shares during the last quarter. Barclays PLC grew its stake in shares of NeuroPace by 346.0% during the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after buying an additional 16,007 shares during the period. Finally, XTX Topco Ltd increased its holdings in shares of NeuroPace by 56.1% during the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after buying an additional 8,643 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.